NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · SMALL CAP
Bionano Genomics, Inc. BNGO
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$28.5M
▼ 7.4% vs FY2024
EPS · FY25
$-4.85
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-66.2%
Net margin · FY25
-92.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 28.5M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 93 cents on every revenue dollar this year.
Per share
USD -4.85
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-66.2%
Return on equity, FY2025
ROE
Operating margin-116.9%
Net margin-92.6%
Return on assets-35.1%
Each USD of equity lost 66 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+27.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.8%
+27.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 73.6M
total assets, end of FY2025
Total assetsUSD 73.6M
EquityUSD 44.4M
CashUSD 3.0M
Current ratio1.98×
Equity funds 60% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.1
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.1
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−4.85
−88.13
−408.60
−4.58
−0.26
−0.39
−1.99
−2.61
−8.65
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−66.2
−170.3
−134.6
−45.2
−38.9
−212.5
−433.7
·
·
Shares out B
0.01
0.00
0.00
0.03
0.29
0.19
0.03
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed